MicroRNAs as therapeutic targets for lung cancer

Lung cancer is one of the leading causes of mortality in the world, indicating the need for innovative therapies for the disease. In recent years, microRNAs have emerged as one of the key players in regulating gene expression. Numerous studies have documented the implications of microRNAs in nearly every carcinogenesis process of lung cancer, including tumor development, apoptosis, invasion and metastasis, as well as anti-cancer drug resistance. Forced expression or suppression of microRNA can regulate the biological alteration during carcinogenesis, underscoring the therapeutic potential of microRNAs in lung cancer. This editorial summarizes recent reports of some key microRNAs that can modulate the lung cancer carcinogenesis process, expound the mechanisms by which they exert their functions, introduce some approaches for manipulating the action of microRNAs, and discuss the perspectives of microRNAs as therapeutic targets for lung cancer.

[1]  Xia Shan,et al.  miR‐181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines , 2010, International journal of cancer.

[2]  Taous Khan,et al.  MicroRNAs: synthesis, mechanism, function, and recent clinical trials. , 2010, Biochimica et biophysica acta.

[3]  B. Liu,et al.  Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  G. González-Aseguinolaza,et al.  Durable correction of inherited metabolic liver disorders requires preventing transgene off-targeting from gene therapy vectors: the value of microRNAs. , 2010, Gastroenterology.

[5]  W. Cho.  Conquering cancer through discovery research , 2010, IUBMB life.

[6]  A. Seto.  The road toward microRNA therapeutics. , 2010, The international journal of biochemistry & cell biology.

[7]  W. Cho.  MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. , 2010, The international journal of biochemistry & cell biology.

[8]  Xin Wu,et al.  MicroRNA‐34a is an important component of PRIMA‐1‐induced apoptotic network in human lung cancer cells , 2010, International journal of cancer.

[9]  K. Kelnar,et al.  Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. , 2010, Cancer research.

[10]  Zhiwei Wang,et al.  Implication of microRNAs in drug resistance for designing novel cancer therapy. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[11]  Yifeng Bai,et al.  Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. , 2010, European journal of cancer.

[12]  A. Fischer,et al.  20 years of gene therapy for SCID , 2010, Nature Immunology.

[13]  M. Rossbach.  Small non-coding RNAs as novel therapeutics. , 2010, Current molecular medicine.

[14]  Douglas D Young,et al.  Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. , 2010, Journal of the American Chemical Society.

[15]  Mariarosaria Incoronato,et al.  miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. , 2010, Cancer research.

[16]  E. Dmitrovsky,et al.  MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. , 2010, The Journal of clinical investigation.

[17]  W. Cho,et al.  MicroRNAs in cancer - from research to therapy. , 2010, Biochimica et biophysica acta.

[18]  E. Barillot,et al.  miR-181a and miR-630 regulate cisplatin-induced cancer cell death. , 2010, Cancer research.

[19]  Robert A. Weinberg,et al.  Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model , 2010, Nature Biotechnology.

[20]  S. Kauppinen,et al.  Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection , 2010, Science.

[21]  Hansjuerg Alder,et al.  miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. , 2009, Cancer cell.

[22]  F. Slack,et al.  Regression of murine lung tumors by the let-7 microRNA , 2009, Oncogene.

[23]  M. Henry,et al.  MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines. , 2009, European journal of cancer.

[24]  Y. Yatabe,et al.  Counterbalance between RB inactivation and miR-17–92 overexpression in reactive oxygen species and DNA damage induction in lung cancers , 2009, Oncogene.

[25]  Alexander Pertsemlidis,et al.  Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. , 2009, Genes & development.

[26]  W. Cho,et al.  Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. , 2009, European journal of cancer.

[27]  Margaret S. Ebert,et al.  MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells , 2007, Nature Methods.

[28]  W. Cho,et al.  MicroRNAs in Cancer Translational Research , 2011 .

[29]  I. Kim,et al.  Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. , 2010, International journal of radiation oncology, biology, physics.